7535-59-3

Basic information

• Product Name: (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE
• Synonyms: (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE;(R)-1-benzyl-5-oxopyrrolidine-2-carboxylic acid;(S)-1-benzyl-5-oxopyrrolidine-2-carboxylic acid
• CAS NO: 7535-59-3
• Molecular Formula: C₁₂H₁₃NO₃
• Molecular Weight: 219.24
• Mol File: 7535-59-3.mol
• Article Data: 20

Chemical Properties

• Melting Point: 90°C
• Boiling Point: 471.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.314±0.06 g/cm3(Predicted)
• PKA: 3.54±0.20(Predicted)
• CAS DataBase Reference: (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE(7535-59-3)
• EPA Substance Registry System: (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE(7535-59-3)

Safety Data

• Hazard Codes: Xi
• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 7535-59-3(Hazardous Substances Data)

Usage

General Description

(S)-1-Benzyl-5-carboxy-2-pyrrolidinone is a chemical compound with a molecular formula C13H13NO3. It is a pyrrolidinone derivative that is used in the synthesis of various pharmaceuticals and as a building block in organic chemistry. (S)-1-BENZYL-5-CARBOXY-2-PYRROLIDINONE has potential applications in the development of drugs for cancer treatment and neurological disorders, due to its ability to inhibit certain enzymes and receptors in the body. It is also used as a chiral auxiliary in asymmetric synthesis, and as a ligand in metal-catalyzed reactions. (S)-1-Benzyl-5-carboxy-2-pyrrolidinone is a valuable chemical intermediate with versatile uses in the fields of medicinal chemistry and chemical synthesis.

Upstream product

• 77539-18-5 (S)-(+)-2-benzylamino glutaric acid 
• 103301-78-6 methyl (2S)-1-benzyl-5-pyrrolidone-2-carboxylate 
• 90741-27-8 (S)-tert-butyl 1-benzyl-5-oxopyrrolidine-2-carboxylate 
• 100-44-7 benzyl chloride 
• 98-79-3 L-Pyroglutamic acid 
• 35418-16-7 L-t-butyl pyroglutamate 
• 100-39-0 benzyl bromide 
• 56-86-0 L-glutamic acid 
• 100-52-7 benzaldehyde 
• 4931-66-2 methyl (S)-pyroglutamate 
• 137641-62-4 (S)-(+)-1-(benzyl)-5-oxopyrrolidine-2-carboxylic acid ethyl ester 

Downstream Products

• 103301-78-6 methyl (2S)-1-benzyl-5-pyrrolidone-2-carboxylate 
• 272784-43-7 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-(4-nitro-phenyl)-propionic acid methyl ester 
• 378238-39-2 9-(N-benzyl-(S)-pyroglutamyl)-β-carboline 
• 412352-94-4 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-(4-trifluoromethanesulfonyloxy-phenyl)-propionic acid methyl ester 
• 412353-17-4 (S)-2-[((S)-1-Benzyl-5-oxo-pyrrolidine-2-carbonyl)-amino]-3-[3-(tert-butyl-dimethyl-silanyloxymethyl)-phenyl]-propionic acid methyl ester 
• 459454-27-4 methyl 3-benzyloxycarbonyl-1-[(1-benzyl-5-oxopyrrolidine-2(S)-carbonyloxy)acetyl]-2-oxoimidazolidine-4(S)-carboxylate 

Relevant articles and documents

Substituted 5-oxo-pyrrolidine derivative, and preparation method and applications thereof

The invention belongs to the technical field of medicine, relates to a substituted 5-oxo-pyrrolidine derivative disclosed in generation formula I, and a preparation method and applications thereof, and more specifically relates to applications of the substituted 5-oxo-pyrrolidine derivative in preparation of anti-cerebral ischemia medicines as a nerve protective agent, and a pharmaceutical composition taking the substituted 5-oxo-pyrrolidine derivative and a pharmaceutically acceptable salt of the substituted 5-oxo-pyrrolidine derivative as active components. The pharmaceutical composition contains the substituted 5-oxo-pyrrolidine derivative and a pharmaceutical excipient and/or a diluent of the substituted 5-oxo-pyrrolidine derivative. In the general formula I, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, Y, and n are defined in the patent specification and patent claims.

3,7-DIAZABICYCLO[3.3.1 ]NONANE CARBOXAMIDES AS ANTITHROMBOTIC AGENTS

The present invention relates to the 3,7-diazabicyclo[3.3.1]nonane carboxamides and process for preparation thereof. The present invention further relates to the compounds of general formula (1) possessing anti-thrombotic (anti-platelet) activities. The invention also relates to use of these moieties as inhibitors of collagen induced platelet adhesion and aggregation mediated through collagen receptors both in vitro and in vivo. Further, invention also relates these class of compounds exhibiting anti-platelet efficacy through dual mechanism inhibited both collagen as well as U46619 (thromboxane receptor agonist) induced platelet aggregation. General formula (1) Wherein, R' is; wherein R is selected from alkyl, acyl, tosyl, tert-butyloxycarbonyl, araalkyl or substituted araalkyl groups; R'' is selected preferably from halogen, cyano, lower alkyl, aryl, substituted aryl, and tosyl groups; R1 is selected from hydrogen and lower alkyl groups; R2 is selected from lower alkyl and aryl groups; R3 is selected from tert-butyloxycarbonyl and bezyloxycarbonyl groups; n = 0,1.

Synthesis and identification of chiral aminomethylpiperidine carboxamides as inhibitor of collagen induced platelet activation

A series of chiral lactam carboxamides of aminomethylpiperidine were synthesized and investigated for the collagen induced in vitro anti-platelet efficacy and collagen plus epinephrine induced in vivo pulmonary thromboembolism. The compound 31a (30 μM/kg) displayed a remarkable antithrombotic efficacy (60% protection) which was sustained for more than 24 h and points to its excellent bioavailability. The compounds 31a (IC50 = 6.6 μM) and 32a (IC50 = 37 μM), as well as their racemic mixture 28i (IC50 = 16 μM) significantly inhibited collagen-induced human platelet aggregation in vitro. Compound 34c displayed dual mechanism of action against both collagen (IC50 = 3.3 μM) and U46619 (IC50 = 2.7 μM) induced platelet aggregation. The pharmacokinetic study of 31a indicated very faster absorption, prolonged and constant systemic exposure and thereby exhibiting better therapeutic response.